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Summary Photodynamic therapy (PDT) for cancer in the oesophagus and bronchi with red (630 nm) light may occasionally lead to wall
perforation and fistula. Therefore, we investigated the clinical use of a less penetrating wavelength (514 nm) forthe curative treatment of nine
superficial carcinomas in the oesophagus and bronchi after photosensitization with Photofrin II. Tumours without infiltration beyond the
submucosa in the oesophagus and beyond the lamina propria in the bronchi were considered as superficial cancers. The outcome and
complications were compared with those of 13 superficial cancers treated with PDT and 630 nm light. In addition, we evaluated histologically
the extent of the long-term tissue damage and scarring following treatment of six oesophageal cancers with either green or red light. At first
endoscopic control, 7-10 days after PDT, tissue necrosis simply matched the illuminated area, without evidence of selective tumour damage.
Six of nine tumours treated with 514 nm light had a complete response compared with nine of 13 after 630 nm irradiation. No perforation or
fistula occurred in either treatment group. However, severe chest pain and fever with or without pleural effusion, consistent with occult
perforation, were observed in three patients after 630 nm illumination in the oesophagus. Histologically, fibrous scarring in the three distinct
sites treated with green light was limited to the superficial layers of the oesophagus. After red light treatment, transmural fibrosis with marked
thinning of the oesophageal wall was evident in two of the three specimens available for inspection. These results indicate that PDT with
514 nm light has the potential to cure superficial cancer in the oesophagus and bronchi with essentially the same probability of success
as red light. In the oesophagus, green light prevents deep tissue damage, thus reducing the risk of perforation.
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Photodynamic therapy (PDT) is emerging as a new form ofcancer
treatment with a potential for cure when applied to early-stage
cancers (Monnier et al, 1990; Bown, 1993; Sibille et al, 1995; Barr
et al, 1996; Grosjean et al, 1996; Hayata et al, 1996; Panjehpour,
1996; Cortese et al, 1997). With PDT, tissue destruction is
achieved by administration of a photosensitizing chemical (PS)
followed by delivery oflight at a wavelength corresponding to one
of the absorption peaks of the drug (Henderson and Dougherty,
1992; Fisher et al, 1995; Stables and Ash, 1995). To date, most of
the clinical investigations of PDT have been carried out with
haematoporphyrin derivative (HPD) or Photofrin II and laser light
near 630 nm (Fisher et al, 1995; Stables and Ash, 1995). This
wavelength has been chosen because ofits increased optical pene-
tration into tissue compared with shorter wavelengths (Wilson et
al, 1985). However, for the treatment of superficial cancers in the
oesophagus and tracheobronchial tree, there is some concern that
PDT with 630 nm light may be responsible for undesirable deep
tissue damage leading to transmural necrosis and life-threatening
complications, such as oesophago-bronchial or oesophago-
tracheal fistula formation (Monnier et al, 1990; Hochain et al,
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1993; Grosjean et al, 1996). For these early cancers, using wave-
lengths that penetrate less than red light should improve the safety
ofthe treatment.
Only a few preclinical (Bellnier et al, 1985; van Gemert et al,
1985; Nseyo et al, 1993; Foster et al, 1996; Nauta et al, 1996) and
clinical (Bandieramonte et al, 1984; Delaney et al, 1993) PDT
studies have been reported with the 514.nm laser light afterphoto-
sensitization with Photofrin II or HPD. These studies have demon-
strated that the destruction of a thin layer of superficial neoplastic
tissue is possible, and that tumour necrosis ofup to 2-3 mm could
be obtained. The thickness ofthe majority ofsuperficial cancers in
the oesophagus and the bronchi does not exceed this depth of
necrosis. Therefore, the use ofgreen light forPDT should be effec-
tive and would decrease the risk ofcomplications causedby exces-
sive tissue penetration of the light combined with the lack of
tumour destruction selectivity.
Hence, we investigated PDT with Photofrin II and 514 nm light
for the clinical treatment of superficial cancers in the oesophagus
and bronchi. The aims of this study were to compare the clinical
outcome and rate of complications after either 514 nm or 630 nm
PDT and to assess the extent of the long-term tissue damage
induced in the oesophagus by either green or red light illumina-
tion. A secondary goal was to evaluate if performing PDT very
shortly after Photofrin II injection would result in a more selective
destruction of tumour tissue. The rationale for choosing a
drug-light interval much shorter than the usual 72 h was the
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Table 1 Results of PDT with Photofrin II
Drug-light interval Bronchi Oesophagus Total
(h)
Tis Microinvasive Tis Tla Tlb
514 nm 72 - 1/1 2/2 2/2 - 5/5
630 nm 72 0/1 2/2 3/3 1/1 2/3 8/10
514 nm 1 - 0/2 - 1/1 0/1 1/4
630 nm 1 - 1/2 - - 0/1 1/3
Numbers indicate the fraction of complete responses with no recurrence as a function of the location, staging, drug-light interval and wavelengths used. Tis,
microinvasive; Tia and Tib refer to tumour staging as described in the Materials and methods section.
Table 2 Extent of the long-term tissue damage after PDT of six superficial cancers in the oesophagus of three patients as a function of the drug and light
parameters used
Patient Site Tumour Drug dose Drug-light Wavelength Light dose Fibrosis/scarring
no. no. staging (mg kg-') interval (h) (nm) (Jcm-2)
1 1 Tia 1 1 514 100 LP,SM
2* Tis 2 72 514 100 LP, SM
3** T1Ta 1 72 630 100 Transmural
2 1 Tia 1 72 514 100 LP, SM
2 Tib 1 72 630 100 LP, SM, MPI
3 1 Tib 2 72 630 100 Transmural
Tis, in situ carcinoma; Tia, intramucosal carcinoma; Ti b, submucosal carcinoma. *Two PDTs to the site 3 months apart with identical drug and light parameters.
**One previous PDT with haematoporphyrin derivative and 630 nm light to this site. LP, lamina propria; SM, submucosa; MPI, muscularis propria interna.
previous observation that the ratio of the fluorescence signal
measured in vivo on the superficial cancer and the adjacent normal
mucosa, namely the fluorescence selectivity, has been found to be
at a maximum very shortly after the drug injection (Braichotte et
al, 1995). The results of this clinical and histological comparison
form the basis ofthis report.
MATERIALS AND METHODS
Patients
Fifteen patients (12 men and three women; mean age 59.8 years,
range 46-79 years) with one or several biopsy-proven superficial
squamous cell carcinomas (SCCs) of the bronchi or the oesoph-
agus were included in the study. All patients had previously
received radiotherapy and/or surgery for aprimary invasive cancer
ofthe head and neck, and their general conditions were somewhat
deteriorated. Thus, PDT was proposed as a minimally invasive
alternative therapy to surgery and, in all cases, was given as the
only treatment. Enrolment was voluntary, and each patient agreed
in writing to participate in the study. The protocol was approved
by the ethics committee ofthe CHUV Hospital in Lausanne.
Definition and staging
Twenty-two superficial bronchial or oesophageal cancers were
included in this study. Tumours in the oesophagus were considered
as 'superficial' SCC ifthey were either: (1) in situ (Tis), intraepithe-
lial with no invasion of the basement membrane; (2) intramucosal,
with no invasion beyond the muscularis mucosae (Tla); or (3)
submucosal, with invasion beyond the muscularis mucosae but
without infiltration of the muscularis propria (Tlb). In the tracheo-
bronchial tree, only in situ (Tis) and microinvasive SCC (carcinoma
notinvading thecartilage and tunicamuscularis ofthebronchi) were
included in the study.
The staging of oesophageal tumours was based on biopsies as
well as on endoscopic criteria as described by Monnier et al
(1994). In a prospective study, these authors showed that these
endoscopic criteria (which include the morphological aspects of
the tumour, i.e. colour change and type of surface irregularity, its
superficial spreading and the presence or absence of a slight
localized rigidity of the oesophageal wall) allowed an accurate
estimation of the in-depth infiltration of superficial cancers in
approximately 90% ofthe cases. In thebronchi, staging was essen-
tially assessed by the evaluation of the tumour's superficial
spreading (Akaogi et al, 1994) and by biopsies. All of the
bronchial neoplasias were roentgenographically occult as evalu-
ated by chest radiography and by computerized tomography.
Photodynamic therapy (PDT)
Photofrin II was kindly supplied by QuadraLogic Technology Inc.
(Vancouver, BC, Canada) as a lyophilized powder and was stored
in the dark at 40C. Shortly before use, it was dissolved in a sterile
5% glucose solution and injected intravenously over a period of
10 min. Doses of 2 mg kg-' (13 injections) or 1 mg kg-' (13 injec-
tions) were used. A dose of 1 mg kg-' was used to reduce the
length of skin photosensitivity and to evaluate whether a lower
drug dose might improve the therapeutic selectivity owing to
enhanced inactivation ofthe drug by photobleaching.
A total of 26 PDT treatments ofthe 22 tumours was performed
under general anaesthesia. Four tumours were treated twice
because ofless than complete response at the 3-month endoscopic
control. The first 15 consecutive treatments (13 tumours) were
performed at 630 nm with an argon ion (Spectra-Physics, model
2045) pumped dye laser (Spectra-Physics, model 375B). In this
British Journal of Cancer (1998) 77(11), 1989-1995 0 CancerResearch Campaign 1998group, the first ten PDTs (ten tumours) were irradiated at 72 h after
the PS administration, whereas in the remaining three tumours
(five PDTs, two tumours treated twice), the PDT was carried out at
a drug-light interval of 1 h after the drug injection.
The subsequent 11 PDTs (nine tumours) were performed at
514 nm using the same argon ion laser operated in the single-line
mode. In this group, thefirst six PDTs (on five tumours) werecarried
out at 72 h after Photofrin II injection, and the next five treatments
(fourtumours) were performed at 1 h afterdrug administration.
All tumours were treated with surface radiation using microlens
and/or cylindrical light distributors in the bronchi, and 180° or
2400 windowed cylindrical light distributors in the oesophagus
(provided by Medlight, Ecublens, Switzerland) (van den Bergh,
1986; van den Bergh et al, 1996).
The irradiance was checked before and after treatment and was
set at 100 mW cm-2 in order to avoid thermal damage. The expo-
sure time was adapted so that the radiant exposure (total light
dose) was 100 J cm-2 at both wavelengths.
Follow-up and interpretation of results
Patients were cautioned to avoid direct sunlight for 4-6 weeks
after drug administration. A first endoscopic follow-up was
performed 7-10 days after PDT to evaluate, macroscopically, the
extent of the tumour necrosis. Subsequent endoscopies, with
oesophageal vital staining (toluidine blue) as well as biopsies and
abrasive or wash cytologies, were performed 3 months after the
treatment and twice a year thereafter.
The patients were classified as having a complete response ifthe
results at follow-up fulfilled all of the following criteria: (a) the
endoscopic examination revealed no macroscopic tumour even
after vital staining in the oesophagus; (b) all biopsy samples were
negative for cancer; and (c) cytological washings or brushings
showed no evidence ofmalignancy. Partial response was recorded
when the endoscopy revealed no visible tumour but residual
cancer persisted on biopsy or cytology. The treatment was consid-
ered a failure (no response) if tumour tissue was visualized at
endoscopy and confirmed by biopsy.
Histopathological studies
One surgical and two necropsy oesophageal specimens ofpatients
previously treated by PDT for one, two and three distinct super-
ficial cancers, respectively, were available for histopathological
examination. The three specimens were available for analysis at 6,
12 and 36 months, respectively, after the last PDT session. None of
these patients had received additional therapy by radiation or
medication to these oesophageal tumours, and none of them had
clinical or endoscopic evidence of gastro-oesophageal reflux
disease. The whole specimen was fixed in 5% buffered formalin.
Multiple serial sections (at least four) from each area treated by
PDT as well as from the non-illuminated adjacent tissue were
embedded in paraffin, processed in a routine manner and stained
with haematoxylin and eosin, van Gieson and Masson's trichrome.
The extent and severity oftissue damage and scarring were evalu-
ated histologically by a senior pathologist who had no previous
knowledge of the PDT parameters used. In addition, the thickness
of the oesophageal wall (from the surface of the epithelium to the
outer border of the muscularis propria) of each treated and adja-
cent non-irradiated areas was measured microscopically using a
graded reticule. A total of ten measurements was recorded serially
on each slide available for inspection.
C
Figure 1 Long-term histological changes after PDT in the oesophagus. The
samples are from sites 2 and 3 and from non-treated oesophagus in patient 1
as described in Table 2. (A) Non-treated area with normal histological architecture. E, epithelium; LP, lamina propria; LMM, lamina muscularis
mucosae; SM, submucosa; MPI, muscularis propria interna; MPE, muscularis
propria externa (H&E, 20 x). (B) After two successive 514 nm PDTs to the
site, scarring and fibrosis are restricted to the superficial layers (LP and SM) of the oesophageal wall as indicated by one asterisk. The LMM has been
destroyed (Van Gieson, 20 x). (C) After 630 nm PDT in an area previously treated with haematoporphyrin derivative and 630 nm light, there is
disappearance of the normal architecture with marked thinning and
transmural scarring (**) of the oesophageal wall (Van Gieson, 20 x)
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Statistical analysis
Means and standard errors of the means were calculated for the
oesophageal wall thickness in the various sites examined.
Comparison of the mean thickness between 514 nm and 630 nm
irradiated areas as well as between treated and non-treated sites
was performed using the Mann-Whitney U-test. A P-value < 0.01
was considered as significant.
RESULTS
Clinical results
Twenty-two superficial SCCs ofthe oesophagus (14 tumours) and
the bronchi (eight tumours) were treated by PDT after Photofrin II
sensitization. Considering all treatment variables, including the
drug dose (1 or 2 mg kg-'), drug light interval (1 h or 72 h) and
wavelength (514 nm or 630 nm), the endoscopic controls 10 days
after PDT revealed necrosis of the tumour and adjacent irradiated
normal mucosa. There was no evidence of selectivity at the tissue
surface, and the extent of the superficial tissue damage simply
matched the geometry ofthe illuminated area.
The clinical results are presented in Table 1. Six of the nine
(67%) superficial cancers treated with 514 nm light achieved a
complete response after one (four tumours) or two (two tumours)
PDT sessions. None of them had recurred after a mean follow-up
of 21 months (range 6-49 months). A partial response was
observed in the three remaining tumours.
In the 630 nm treatment group (13 tumours), complete response
without relapse was recorded in nine cases (69%), with disease-
free follow-up periods ranging from 6 to 85 months (mean 26
months). Cure was achieved after one PDT session in eight of the
nine tumours and after two treatments 3 months apart in the last
one. Three cancers achieved a partial response, and one exhibited
only a minimal macroscopic reduction in size.
In the oesophagus, PDT with either green or red light was
highly effective in eradicating in situ and intramucosal (Tla)
cancer but failed to cure more than half of the submucosal (Tlb)
tumours.
Ten of the 26 PDTs were carried out on seven tumours (three
tumours treated twice) at a drug-light interval of 1 h after
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Photofrin II injection. Although tumour tissue necrosis was
observed at the first endoscopic control, only two ofthese tumours
achieved a complete response (Table 1).
Complications
No major complications, such as stenosis, perforation or fistula,
were observed in either treatment group. However, three patients
treated with red light reported severe chest pain, with associated
high-grade fever for 10 days after PDT. Two of them, with early
cancer in the lower oesophagus, had concomitant pleural effusion.
The third, whose cancer was located on the left wall of the upper
oesophagus, showed endoscopic evidence of oedema and
erythema on the posterior wall of the trachea at the level of the
oesophageal cancer. These three patients recovered fully under
antimicrobial therapy. No such side-effects were noted after green
light PDT.
Histopathological study
Three specimens ofoesophagus, each with either one, two or three
distinct areas previously treated by PDT were available for study
ofthe long-term tissue damage induced by PDT (Table 2). In each
of the treated sites, healing and re-epithelialization were macro-
scopically complete. Microscopically, the wall of the non-PDT-
treated oesophagus consisted of well distinguishable anatomical
layers (Figure IA); the lamina propria and submucosa consisted of
loose connective tissue with scanty cellular components and blood
vessels. In all ofthe treated areas, the epithelium was morphologi-
cally normal without residual cancer.
The three sites treated with 514 nm PDT showed evidence of
scarring with collagen fibre deposits in the lamina propria and
submucosa and disappearance of the lamina muscularis mucosae
(Figure 1B). Focal areas of interstitial fibrosis and occasional
atrophic smooth muscle fibres were also noted in the uppermost
layers ofthe muscularis propria. However, the deeper layers ofthe
muscularis propria did not display any morphological changes or
fibrosis compared with non-treated sites. More dramatic changes
were observed in the areas treated with red light. In two instances,
the normal microscopic architecture of the oesophageal wall was
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Figure 2 Thickness of the oesophageal wall (mean ±s.e.) after PDT with 514 nm or 630 nm light for six distinct superficial cancers in the three patients
reported in Table 2. Measurement of a non-irradiated area of the oesophagus of each patient is given as a control. *One previous PDT with haematoporphyrin
derivative and 630 nm light to this site
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completely blunted and replaced by dense collagen fibre deposi-
tion leading to transmural scarring (Figure IC). In these two sites,
only very few residual and markedly atrophic smooth muscle
fibres were noted in the external part of the muscularis propria.
Wherever present, the perioesophageal fat was also partially
replaced by dense fibrosis. Although one of these two areas had
received one previous PDT with HPD and red light, the second one
displayed similar changes after a single treatment with Photofrin II
and red light. Finally, in the third case, fibrous scarring completely
replaced the muscularis propria interna. The externa was some-
what preserved but still exhibited some degree of interstitial
fibrosis surrounding atrophic muscle fibres.
Compared with non-irradiated areas, PDT led to a significant
(P < 0.0001) reduction of the oesophageal wall thickness in all but
one of the green light-treated sites (P = 0.09) (Figure 2, patient 1).
Furthermore, red light induced significantly (P < 0.0001) more
pronounced thinning than did green light PDT, the reduction of the
wall thickness being especially marked in the site previously
treated with HPD-PDT and red light.
DISCUSSION
Photodynamic therapy of cancer in the oesophagus and the
tracheobronchial tree may occasionally result in severe complica-
tions, such as wall perforation, oesophago-tracheal fistula or stric-
ture formation (Monnier etal, 1990; Hochain et al, 1993; Grosjean
et al, 1996; McCaughan et al, 1996). Whereas massive tumour
destruction may account for such a dramatic event after palliative
PDT of adeep infiltrating cancer, transmural necrosis after PDT of
a superficial carcinoma can only be explained by the non-selective
damage of the healthy tissue underlying the tumour. This, in turn,
is the result of the insufficient ratio between the PS concentration
in the tumour and that in the underlying normal tissue, combined
with the use ofdeep penetrating wavelengths oflight.
In situ and microinvasive squamous cell carcinomas of the
bronchi and the oesophagus are usually flat, slightly elevated or
slightly depressed lesions, no thicker than 1 or 2 mm. For PDT of
such tumours, the use ofwavelengths that are less penetrating than
the usual red light permits the selective illumination of only the
superficial layers ofthe organ (Bays et al, 1996), thus avoiding the
effect of insufficient selectivity ofthe PS distribution. Undesirable
deep tissue damage can therefore be avoided, while keeping a high
degree of PDT efficacy at lesser depths. Experimental animal
studies have confirmed that HPD photosensitization with green
light at 514 nm is very effective in inducing superficial tissue
necrosis to depths of up to 2-3 mm (Bellnier et al, 1985; van
Gemert et al, 1985). Our endoscopic examination 7-10 days after
PDT showed superficial tissue necrosis in all instances without
any real macroscopic difference in the amount ofdamage between
the two treatment wavelengths. These observations are in agree-
ment with those madeby Nauta et al (1996) on the effects ofgreen
or red light on normal palatal mucosa in rats.
Clinically, our results show that PDT with Photofrin II and
green light was highly effective in eradicating in situ and intramu-
cosal (T1a) SCC in the oesophagus and that the complete response
rate (100%) was equal to that obtained with red light. Results of
PDT were, however, less satisfactory for bronchial and submu-
cosal oesophageal cancer, with a slight trend towards better effi-
cacy for red light treatment. Overall, the rate ofcomplete response
achieved with green light (67%) was not markedly different from
the 69% of complete responses recorded after red light PDT.
However, the small number of tumours in each treatment group
does not allow the conclusion that the two wavelengths have
completely equivalent efficacy. The results are, however, consis-
tent with this hypothesis and are also in agreement with some
preclinical and clinical reports from the literature showing that thin
cancers can be controlled efficiently with either green or red light
PDT (Bandieramonte et al, 1984; Foster et al, 1996).
No overt fistula was recorded in either treatment group. However,
three patients treated with red light for oesophageal cancer exhibited
severe side-effects (pain, fever and/or pleural effusion) that were
interpreted as possible occult perforation. Interestingly, the histolog-
ical analysis of the oesophagus of two of these patients (patients 1
and 3 in Table 2) displayed transmural scarring with marked thin-
ning of the wall, thus confirming previous extensive tissue damage.
It is also worth pointing out that in none of these three patients was
the tumour located on the anterior wall ofthe upper oesophagus and
thusjust opposite to the posterior wall ofthe trachea. Outside ofthis
critical location, transmural necrosis of the oesophagus may be
confined by perioesophageal fat, thus leading to a covered perfora-
tion rather than to overt fistula.
Although only a few specimens were available for histological
study, the results were consistent and showed that, whatever the
treatment conditions and wavelengths used, PDT leads to some
long-term localized tissue damage with fibrous scarring and thin-
ning ofthe oesophageal wall. As the irradiance was always kept at
100 mW cm-2, a concomitant thermal effect can certainly be ruled
out (van Gemert andWelch, 1989), and the morphological changes
observed mustbe considered the results ofPDT only. The in-depth
extent of the long-term tissue damage was, however, wavelength
dependent: while full-thickness scarring and marked thinning of
the oesophageal wall was evident afterred light illumination, espe-
cially after two treatments at the same site, the fibrosis after one or
two PDTs with green light never extended deeper than the most
superficial layers ofthe muscularis propria. Thus, with green light,
wall perforation was not expected to occur.
The contrasting effect of green and red light on the depth of
scarring induced in the oesophageal wall is further emphasized if
the respective Photofrin absorption coefficients (Bellnier et al,
1985) at both wavelengths used are considered. Taking this factor
into account, it can be calculated that, for a given radiant energy
fluence, the dose absorbed at 514 nm by a Photofrin II molecule is
about three times greater than it is at 630 nm. Combining these
factors with the optical properties ofthe oesophageal wall for 514
nm and 630 nm respectively (Bays et al, 1997), it can be estimated
that, in our setting, the 100 J cm-2 green light radiant exposure
(total light dose) was equivalent to approximately 235 J cm-2 of
red light. Nevertheless, and owing to the greater absorption by the
tissue of green light relative to red light (Bays et al, 1997), the
damage in the areas treated with 514 nm PDT was always limited
to the upper layers ofthe oesophageal wall. This simply underlines
that the use ofgreen light greatly enhances the 'in-depth' necrosis
selectivity as well as the safety of PDT for the treatment of super-
ficial cancer in the oesophagus.
Finally, and although this was not the main purpose of the
present study, ten PDTs were carried out as early as 1 h, instead of
72 h, after the injection of Photofrin II. This was motivated by a
previous in vivo fluorescence pharmacokinetic study in patients
with early SCC in the upper aerodigestive tract, which showed
that, although the Photofrin II fluorescence in both tumour and
normal mucosa reached a maximum intensity between 10 and 15 h
after injection and plateaued thereafter, the highest fluorescence
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ratio between early cancer and adjacent normal mucosa was
observed within the first hour after the injection (Braichotte et al,
1995). It was therefore hoped that this improved fluorescence
contrast would result in better therapeutic selectivity. Selective
tumour necrosis was, however, never observed, no matter what
drug-light interval was used. Performing PDT 1 h after Photofrin
II injection was, however, associated with a poor outcome, and
only two out of the seven superficial cancers treated achieved a
complete response. Two possible explanations can be put forward.
First, at such a short drug-light interval, most of the injected
Photofrin is probably located in or near the vasculature, and
vascular shutdown only, without associated direct phototoxic
cellular kill (Henderson and Dougherty, 1992), is probably to be
expected after the administration of the light. As early SCC are
only poorly or not at all vascularized, this vascular damage alone
may be insufficient to eradicate the tumour. Secondly, the photo-
dynamic dose at the tumour bed may have been insufficient at this
short drug-light interval. This is substantiated by the fact that, at
very short delays after injection, the intensity of the fluorescence
signal of Photofrin II, which is known to correlate more or less
with the drug concentration, is much lower than at 72 h after the
drug administration (Braichotte et al, 1995). The low concentra-
tion of the dye in the tumour combined with attenuation of the
incident light may be insufficient to reach the photodynamic
threshold in the deeper part of the tumour, thus leading to incom-
plete response.
In summary, our study suggests that, for the curative treatment
of in situ (Tis) and intramucosal (Tla, NO stage) cancer in the
oesophagus, green light PDT with Photofrin II permits specific
damaging ofonly the superficial layers ofthe wall and thus greatly
reduces the risk ofperforation, while maintaining a high degree of
efficacy. For identical indications, very good clinical results have
also been obtained with green light after photosensitization with
the second-generation photosensitizer m-tetra(hydroxyphenyl)
chlorin (Grosjean et al, 1996; Savary et al, 1997). In the tracheo-
bronchial tree, except for the membranous part of the trachea and
the main bronchi, the presence of cartilage, which takes up little
PS (Smith et al, 1993; Andrejevic et al, 1996), renders perforation
almost impossible. In these cases, green light may offer no advan-
tage over red light.
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